Galli M, Benenati S, Capodanno D, et al. - By conducting this systematic review and meta-analysis, researchers examined the safety as well as efficacy of guided vs standard selection of antiplatelet therapy in patients receiving percutaneous coronary intervention (PCI). Relevant randomised controlled trials and observational studies were identified from MEDLINE (via PubMed), Cochrane, Embase, and Web of Science databases. Overall, 11 randomised controlled trials and three observational studies, comprising 20,743 patients, were analyzed. Trial-defined primary major adverse cardiovascular events and any bleeding were coprimary endpoints. All-cause mortality, cardiovascular death, myocardial infarction, stroke, definite or probable stent thrombosis, and major and minor bleeding, all were assessed as key secondary endpoints. Per findings, guided selection of antiplatelet therapy not only conferred improvements in both composite and individual efficacy outcomes but also displayed a favourable safety profile, driven by a decrease in minor bleeding, favouring the use of platelet function or genetic testing to optimise the selection of agent in patients receiving PCI.